The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21

Cancer Biology and Therapy

Volumn 9, Issue 11, 2010, Pages 928-935

  Son, Deok Soo ^a   Wilson, Andrew J ^b   Parl, Angelika K ^a   Khabele, Dineo ^b  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Cell cycle control; COX inhibitors; HDAC inhibitors; Ovarian cancer; p21; Romidepsin

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; P21 ACTIVATED KINASE; PROTEASOME; ROMIDEPSIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE REGULATION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; UPREGULATION; CELL CYCLE; CELL PROLIFERATION; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ASPIRIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 1; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; OVARIAN NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 79952279235     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.11.11873     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009.
2. Chobanian N, Dietrich CS, 3rd. Ovarian cancer. Surg Clin North Am 2008; 88:285-99.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29.
4. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26:995-1005.
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84.
6. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009.
7. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10:32-42.
8. Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther 2007; 6:795-801.
9. Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008; 10:1021-7.
10. Lech-Maranda E, Robak E, Korycka A, Robak T. Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity. Mini Rev Med Chem 2007; 7:1062-9.
11. Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 109:182-6.
12. Sonnemann J, Huls I, Sigler M, Palani CD, Hong le TT, Volker U, et al. Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol Rep 2008; 20:219-24.
13. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90:11693-7.
14. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2010; 19:435-42.
15. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63:906-11.
16. Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, et al. Extracellular signal-regulated kinase is a target of cyclooxygenase-1- peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res 2007; 67:5285-92.
17. Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, et al. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 2006; 66:2527-31.
18. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005; 65:3735-44. (Pubitemid 40616351)
19. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006; 5:2606-12.
20. DTP N. NCI-60 DTP Human Tumor Cell Line Screen. NCI/NIH 2010.
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
22. Khabele D, Lopez-Jones M, Yang W, Arango D, Gross SJ, Augenlicht LH, et al. Tumor necrosis factor-alpha related gene response to Epothilone B in ovarian cancer. Gynecol Oncol 2004; 93:19-26. (Pubitemid 38429544)
23. cip1/waf1. Int J Biochem Cell Biol 2007; 39:1367-74.
24. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003; 115:71-82. (Pubitemid 37255319)
25. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 2006; 281:29228-35.
26. Urick ME, Giles JR, Johnson PA. Dietary aspirin decreases the stage of ovarian cancer in the hen. Gynecol Oncol 2009; 112:166-70.
27. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NFkappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136:416-25.